Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,230 recruiting studies in this area right now.
By phase
- Not applicable3,143
- Phase 21,065
- Phase 1821
- Phase 1/Phase 2445
- Phase 3424
- Phase 4238
- Phase 2/Phase 394
Top conditions
- Multiple Sclerosis341
- Multiple Myeloma332
- Asthma194
- Lymphoma182
- Rheumatoid Arthritis141
- Type 1 Diabetes133
- Atopic Dermatitis128
- Systemic Lupus Erythematosus125
- Acute Lymphoblastic Leukemia122
- HIV Infections116
- Chronic Lymphocytic Leukemia100
- Autoimmune Diseases81
- Follicular Lymphoma74
- Diabetes Mellitus, Type 169
- Hodgkin Lymphoma67
- Rheumatoid Arthritis (RA)66
- Leukemia64
- Acute Myeloid Leukemia62
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China91
- National Institute of Allergy and Infectious Diseases (NIAID)90
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris70
- M.D. Anderson Cancer Center63
- Novartis Pharmaceuticals63
- AstraZeneca57
- City of Hope Medical Center47
- Mayo Clinic46
- Memorial Sloan Kettering Cancer Center44
Where studies are running
- California494
- Maryland196
- Alabama175
- Florida143
- Arizona140
- New York123
- Massachusetts119
- Texas118
- Illinois81
- Colorado77
Recruiting studies6,230 total
- NCT05292664RecruitingPhase 1
Venetoclax trial for high-risk blood cancers in young patients
This Phase 1 study tests venetoclax to treat certain high-risk blood cancers in children, teens, or young adults. It is designed to see if the drug can work safely for patients whose disease has returned or did not respond to prior treatment.
San Francisco, CaliforniaAges 1–40 - NCT05294055RecruitingPhase 2
Mecapegfilgrastim to help collect stem cells for transplant
This Phase 2 study tests mecapegfilgrastim with chemotherapy to help your body collect enough peripheral blood stem cells for an autologous transplant (using your own cells). It’s for people with multiple myeloma or certain lymphomas who have already had some response to treatment.
Hefei, AnhuiAges 18–65 - NCT05294367RecruitingEarly Phase 1
Magnesium by diet or skin lotion for people with lymphoma
This early study tests whether replacing magnesium—either by diet or a topical (skin) supplement—can improve safety or other health measures in people with lymphoma. It focuses on people who have a slightly low magnesium level and checks blood magnesium repeatedly during the study.
Rochester, MinnesotaAges 18 years+ - NCT05294731RecruitingPhase 1/Phase 2
Study drug for certain B-cell cancers in Chinese participants
This early-stage study tests a new medicine (BGB-16673) that targets B-cell cancer cells in people with specific lymphoma or related blood cancers. It aims to see how well the drug can control the cancer and what side effects it causes, especially in Chinese participants.
Bengbu, AnhuiAges 18 years+ - NCT05296070RecruitingPhase 2
Loncastuximab for relapsed or treatment-resistant marginal zone lymphoma
This Phase 2 study tests loncastuximab tesirine, a medicine that targets lymphoma cells, in people with marginal zone lymphoma that came back or did not respond to prior treatment. It aims to see how well the treatment can control the disease and shrink lymphoma in the body.
Duarte, CaliforniaAges 18 years+ - NCT05296304RecruitingPhase 1
Bexarotene plus radiation for mycosis fungoides skin lymphoma
This Phase 1 study tests whether the medicine bexarotene combined with radiotherapy can shrink or control mycosis fungoides, a skin lymphoma. It also looks at how safe the combination is and how the body handles the treatment.
Commack, New YorkAges 18 years+ - NCT05299424RecruitingPhase 1/Phase 2
CM336 for multiple myeloma after prior treatments
This trial tests CM336, a new medicine, in people with multiple myeloma that has returned (relapsed) or not responded (refractory) to standard treatments. It may help by trying a different approach when other key medicines have already been tried.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05300035RecruitingPhase 2
HIV treatment add-on antibodies during early infection
This study tests whether adding two antibody medicines to standard HIV treatment helps people control HIV better after stopping treatment. It focuses on people with recently diagnosed (“primary”) HIV infection, aiming to improve long-term control after ART is interrupted.
BobignyAges 18–70 - NCT05300282RecruitingPhase 1/Phase 2
Atezolizumab plus chemotherapy for Hodgkin lymphoma after relapse
This trial studies whether adding atezolizumab to a chemotherapy-type treatment (the BEGEV regimen) can shrink Hodgkin lymphoma that has come back or did not respond. It may help people who have only had one prior whole-system (systemic) treatment and can still receive stem cell transplant (ASCT).
Alessandria, AlessandriaAges 18–60 - NCT05302934Recruiting
Testing a knee-surgery app and sensor after knee replacement
This trial checks whether a data platform that uses a wearable sensor and a phone app works well for people getting a total knee replacement. It may help make follow-up care more organized and easier by capturing recovery information.
Konstanz, Baden-WurttembergAges 18 years+ - NCT05303337Recruiting
Study of gut and HIV changes after switching to long-acting shots
This trial compares how HIV “reservoirs,” inflammation, and the gut microbiome change when people switch from daily HIV pills to long-acting injectable treatment. It may help you and your team understand what to expect with the switch and how your body responds.
MarseilleAges 18 years+ - NCT05305066Recruiting
Study for people with rheumatoid arthritis who tried standard medicines
This trial studies an add-on treatment approach for rheumatoid arthritis (RA) in adults whose symptoms did not improve with standard “first-line” medicines. It may help people who still have active RA after trying certain disease-modifying drugs.
Montreal, QuebecAges 18 years+ - NCT05310591RecruitingPhase 1/Phase 2
Study anti-PD1 treatment with Kymriah re-dosing for leukemia
This Phase 1/2 trial studies giving an anti-PD1 antibody (like pembrolizumab or nivolumab) along with a second Kymriah (tisagenlecleucel) infusion in children and young adults whose B-cell leukemia is coming back or their Kymriah effect has faded. It may help the new immune treatment work better after the first Kymriah.
BordeauxAges 1–25 - NCT05310799Recruiting
Personalized risk estimates for children with newly diagnosed JIA
This study looks at how best to estimate a child’s likely symptoms and treatment response in the first phase after a new JIA diagnosis. It may help families and clinicians make clearer, more personalized decisions about care.
Vancouver, British ColumbiaAges 1–18 - NCT05312255Recruiting
Non-drug help to improve quality of life in myeloma
This study tests non-chemotherapy supports meant to improve quality of life and immune health for people with multiple myeloma (or related conditions). Depending on the group, it may involve activities, nutrition, and/or a medication like a beta blocker.
Buffalo, New YorkAges 18 years+ - NCT05313243RecruitingPhase 2
Pembrolizumab plus brentuximab for relapsed T-cell lymphoma
This Phase 2 study tests pembrolizumab together with brentuximab for people whose T-cell non-Hodgkin lymphoma has come back or stopped responding to treatment. It may help shrink the lymphoma and improve long-term control by boosting the immune system and targeting a protein called CD30.
New Haven, ConnecticutAges 18 years+ - NCT05312801RecruitingPhase 1
Testing BAFF CAR-T for relapsed or resistant non-Hodgkin lymphoma
This Phase 1 study tests a new immune cell treatment (BAFF CAR-T) for people with non-Hodgkin lymphoma that has come back or did not respond well to treatment. It aims to see how safe it is and whether it can help control the lymphoma.
Cleveland, OhioAges 18 years+ - NCT05315141Recruiting
Study of AAV in people with ANCA-associated vasculitis
This study follows people with ANCA-associated vasculitis to better understand the treatment using AAV. Your participation would mainly involve agreeing to be in the study and meeting the study’s disease criteria.
Changsha, HunanAges Any age - NCT05315726Recruiting
Vibration therapy to reduce stiffness after stroke
This trial studies whether regular muscle vibration can reduce post-stroke muscle stiffness and improve how the brain and nerves adapt. If you’re in the right stage after stroke, it may help improve arm and hand movement.
Chalon-sur-SaôneAges 18 years+ - NCT05317455RecruitingEarly Phase 1
Studying brain sugar changes in adults with risky low blood sugar
This early-stage study looks at how the brain uses sugar in people with type 1 diabetes who have had severe or hard-to-notice low blood sugar. It may help researchers understand the brain effects of low blood sugar and guide safer care.
New Haven, ConnecticutAges 18–55 - NCT05318196Recruiting
Predict kidney disease risk and progression from patient data
This trial looks at ways to predict how kidney disease may develop, change, or cause complications using information from patients. It may help doctors identify people at higher risk and tailor care earlier.
ToulouseAges 18–99 - NCT05320835Recruiting
Talk-based overdose prevention for people using opioids
This trial tests an overdose prevention approach for people who have used opioids recently. It aims to help reduce the risk of overdose by offering a structured prevention intervention.
Baltimore, MarylandAges 18 years+ - NCT05323357Recruiting
Study using gut samples to understand germs and your immune system
This study collects gut tissue (biopsies) and blood to learn how gut germs (microbes) and the immune system interact. It may help researchers understand why gut infections or immune problems happen and improve future treatments.
BernAges 18–80 - NCT05326061Recruiting
Study for people at high risk of getting HIV
This registry study looks at people who are HIV-negative but at high risk of getting HIV, to better understand risk and care needs. If you qualify, you may be asked to share health and behavior information to help guide future prevention efforts.
ViennaAges 18–100
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,230 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,742 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.